- Home
- PMI vs DCTH Comparison
PMI vs DCTH Comparison
Compare PMI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMI
- DCTH
- Stock Information
- Founded
- PMI 1981
- DCTH 1988
- Country
- PMI United States
- DCTH United States
- Employees
- PMI N/A
- DCTH N/A
- Industry
- PMI
- DCTH Medical/Dental Instruments
- Sector
- PMI
- DCTH Health Care
- Exchange
- PMI Nasdaq
- DCTH Nasdaq
- Market Cap
- PMI 414.4M
- DCTH 388.3M
- IPO Year
- PMI 2025
- DCTH N/A
- Fundamental
- Price
- PMI $5.82
- DCTH $11.65
- Analyst Decision
- PMI
- DCTH Strong Buy
- Analyst Count
- PMI 0
- DCTH 4
- Target Price
- PMI N/A
- DCTH $24.50
- AVG Volume (30 Days)
- PMI 3.1M
- DCTH 565.2K
- Earning Date
- PMI 01-01-0001
- DCTH 11-07-2025
- Dividend Yield
- PMI N/A
- DCTH N/A
- EPS Growth
- PMI N/A
- DCTH N/A
- EPS
- PMI N/A
- DCTH 0.06
- Revenue
- PMI $3,031,000.00
- DCTH $70,240,000.00
- Revenue This Year
- PMI N/A
- DCTH $159.22
- Revenue Next Year
- PMI N/A
- DCTH $41.22
- P/E Ratio
- PMI N/A
- DCTH $208.23
- Revenue Growth
- PMI N/A
- DCTH 491.35
- 52 Week Low
- PMI $4.19
- DCTH $8.08
- 52 Week High
- PMI $7.12
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- PMI N/A
- DCTH 58.67
- Support Level
- PMI N/A
- DCTH $10.81
- Resistance Level
- PMI N/A
- DCTH $11.32
- Average True Range (ATR)
- PMI 0.00
- DCTH 0.46
- MACD
- PMI 0.00
- DCTH 0.14
- Stochastic Oscillator
- PMI 0.00
- DCTH 85.03
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing an implantable Total Artificial Heart. It is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including TAH. The TAH is an implantable system designed to assume the full function of a failed human heart in patients suffering from advanced heart failure.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.